Compugen to Present at the Unterberg, Towbin Life Sciences Conference
26 Octubre 2006 - 7:00AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) announced today that Martin Gerstel,
Chairman of the Board, is scheduled to present at the upcoming
Unterberg, Towbin Life Sciences Conference at 11:30 AM (Eastern
Time) on Monday, October 30, 2006 at the Palace Hotel in New York
City. A live Webcast of the presentation will be available at
http://www.wsw.com/webcast/ceut5/cgen/, and on Compugen�s Website.
A replay will be available for 90 days following the presentation.
About Compugen Compugen�s mission is to be the world leader in the
discovery and licensing of product candidates to the drug and
diagnostic industry. The Company�s powerful discovery engines
enable the predictive discovery of numerous potential therapeutics
and diagnostic biomarkers. This capability results from the
Company�s decade-long pioneering efforts in the deeper
understanding of important biological phenomena at the molecular
level through the incorporation of ideas and methods from
mathematics, computer science and physics into biology, chemistry
and medicine. To date, Compugen�s product discovery efforts and its
initial discovery engines have focused mainly within the areas of
cancer, immune-related and cardiovascular diseases. The Company's
primary commercialization pathway for its therapeutic and
diagnostic product candidates is to enter into milestone and
revenue sharing out-licensing and joint development agreements with
leading companies. Compugen has established an agricultural
biotechnology affiliate � Evogene, and a small-molecule drug
discovery affiliate � Keddem Bioscience. For additional
information, please visit Compugen's corporate Website at
www.cgen.com. Compugen Ltd. (NASDAQ: CGEN) announced today that
Martin Gerstel, Chairman of the Board, is scheduled to present at
the upcoming Unterberg, Towbin Life Sciences Conference at 11:30 AM
(Eastern Time) on Monday, October 30, 2006 at the Palace Hotel in
New York City. A live Webcast of the presentation will be available
at http://www.wsw.com/webcast/ceut5/cgen/, and on Compugen's
Website. A replay will be available for 90 days following the
presentation. About Compugen Compugen's mission is to be the world
leader in the discovery and licensing of product candidates to the
drug and diagnostic industry. The Company's powerful discovery
engines enable the predictive discovery of numerous potential
therapeutics and diagnostic biomarkers. This capability results
from the Company's decade-long pioneering efforts in the deeper
understanding of important biological phenomena at the molecular
level through the incorporation of ideas and methods from
mathematics, computer science and physics into biology, chemistry
and medicine. To date, Compugen's product discovery efforts and its
initial discovery engines have focused mainly within the areas of
cancer, immune-related and cardiovascular diseases. The Company's
primary commercialization pathway for its therapeutic and
diagnostic product candidates is to enter into milestone and
revenue sharing out-licensing and joint development agreements with
leading companies. Compugen has established an agricultural
biotechnology affiliate - Evogene, and a small-molecule drug
discovery affiliate - Keddem Bioscience. For additional
information, please visit Compugen's corporate Website at
www.cgen.com.
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024